Application
Western blot analysis of ALPPL2 over-expressed 293 cell line, cotransfected with ALPPL2 Validated Chimera RNAi ( Cat # H00000251-R01V ) (Lane 2) or non-transfected control (Lane 1). Blot probed with ALPPL2 monoclonal antibody (M07), clone 2B3 (Cat # AT1125a ). GAPDH ( 36.1 kDa ) used as specificity and loading control.Application
Western Blot analysis of ALPPL2 expression in transfected 293T cell line by ALPPL2 monoclonal antibody (M07), clone 2B3.Lane 1: ALPPL2 transfected lysate(57.5 KDa).Lane 2: Non-transfected lysate.| Product Name | ALPPL2 Antibody (monoclonal) (M07) |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | ALPG, ALPPL, GCAPalkaline phosphatase, placental-like 2 |
| Clonality | Monoclonal |
|---|---|
| Isotype | IgG2a |
| Clone Number | 2B3 |
| Host Species | Mouse |
| Tested Applications | WB |
| WB:1:500~1000 |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Alternative Names | ALPG ALPPL GCAPalkaline phosphatase placental-like 2 |
|---|---|
| Molecular Weight(MW) | 57377 Da |
| Tissue Specificity | ALPPL2 (NP_112603, 365 a.a. ~ 455 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
Application
Western blot analysis of ALPPL2 over-expressed 293 cell line, cotransfected with ALPPL2 Validated Chimera RNAi ( Cat # H00000251-R01V ) (Lane 2) or non-transfected control (Lane 1). Blot probed with ALPPL2 monoclonal antibody (M07), clone 2B3 (Cat # AT1125a ). GAPDH ( 36.1 kDa ) used as specificity and loading control.
Application
Western Blot analysis of ALPPL2 expression in transfected 293T cell line by ALPPL2 monoclonal antibody (M07), clone 2B3.Lane 1: ALPPL2 transfected lysate(57.5 KDa).Lane 2: Non-transfected lysate.| Application Notes | WB:1:500~1000 |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
